DIOKA THERAPEUTICS

INNOVATING HYPERTENSION TREATMENT

ABOUT US

We are working at the University of Aberdeen to develop a new medicine treating high blood pressure. The work is based on an exciting discovery led by Dr Guy Bewick and Dr Bob Banks that has uncovered a natural mechanism the body uses to regulate blood pressure. We believe that targeting this mechanism with a new medicine will provide a completely new way to treat this disease that is often referred to as ‘a silent killer’.

What we do



Global Impact

High blood pressure is a leading cause of premature deaths worldwide.



Breakthrough Discovery

We have identified a new way to significantly improve blood pressure regulation.



Current Medications

1 in 3 people with high blood pressure cannot control it, even with medication.



Innovative Medicine

We are developing a novel drug that leverages this discovery to provide better blood pressure control with fewer side effects.



Side Effects

Existing treatments often require multiple drugs, causing side effects like tiredness, dizziness, headaches, and nausea.



Improved Health

Our aim is to offer a more effective treatment for high blood pressure, enhancing the quality of life for millions globally.

WATCH OUR VIDEO

“Reducing Side Effects and Providing a More Effective Treatment for Hypertension.”

Contact Us

Your voice matters

Together, we can revolutionise hypertension treatment.

PATIENT SURVEY

PHARMA SURVEY

MEET THE TEAM

Guy Bewick

CSO



A leading neuroscience innovator and Senior Lecturer at the University of Aberdeen, Guy’s research focus is understanding nerve terminal functional regulation, seeking therapeutic neural targets for conditions such as blood pressure control, ALS, ataxia and fibromyalgia.

Robert Banks

DeputySO



Bob’s research primarily focuses on the structure and function of muscle spindles. Together with Guy, he discovered a glutamatergic system that regulates the sensitivity of mechanosensory nerve endings, including baroreceptors.

David Blackbourn

CEO



Head of Medicine, Medical Sciences & Nutrition, University of Aberdeen, and a qualified executive coach, David leverages his deep entrepreneurial experience, notably as co-founder of Ducentis BioTherapeutics (acquired by Arcutis Biotherapeutics in 2022).